Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

mogamulizumab 6Cyclophosphamide 5ruxolitinib 3pembrolizumab 3Immunoglobulin G 3Disulfides 3Biopsy 3fludarabine 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Brentuximab Vedotin 2Blood Specimen Collection 2tofacitinib 1sodium-iodide symporter 1hypericin 1fludarabine phosphate 1cemiplimab 1X-Rays 1Vincristine 1Urine Specimen Collection 1Prednisone 1Positron-Emission Tomography 1Photopheresis 1Photons 1Nivolumab 1Mycophenolic Acid 1Methoxsalen 1Mesna 1Melphalan 1MAC-ST-001 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell, Cutaneous × EPOCH protocol × Clear all
NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡